Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells $31,185.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $6.93, for a total value of $31,185.00. Following the sale, the director now directly owns 69,938 shares of the company’s stock, valued at approximately $484,670.34. This represents a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Duncan Gallagher also recently made the following trade(s):

• On Monday, December 23rd, Duncan Gallagher sold 4,500 shares of Health Catalyst stock. The shares were sold at an average price of $6.98, for a total value of $31,410.00.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $7.42 on Friday. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a market capitalization of $451.51 million, a P/E ratio of -5.50 and a beta of 1.31. The business has a 50 day moving average price of $7.86 and a 200 day moving average price of $7.49. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same period in the previous year, the business earned ($0.22) earnings per share. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. Sell-side analysts expect that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Evercore ISI increased their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Citigroup increased their target price on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Royal Bank of Canada increased their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Finally, Stephens increased their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus price target of $11.59.

Institutional Investors Weigh In On Health Catalyst

Large investors have recently bought and sold shares of the stock. Primecap Management Co. CA grew its holdings in Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after buying an additional 305,079 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in Health Catalyst during the 3rd quarter valued at $897,000. Fred Alger Management LLC acquired a new stake in Health Catalyst during the 3rd quarter valued at $6,858,000. Millrace Asset Group Inc. acquired a new stake in Health Catalyst during the 3rd quarter valued at $1,568,000. Finally, Point72 Asset Management L.P. grew its holdings in Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after buying an additional 211,805 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.